ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Radiation Therapy in Treating Women With Localized Breast Cancer

This study has been completed.

Sponsored by: Institute of Cancer Research, United Kingdom
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00107497
  Purpose

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways and giving it after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This randomized clinical trial is studying radiation therapy to see how well it works in treating women with localized breast cancer.


Condition Intervention
Breast Cancer
Procedure: adjuvant therapy
Procedure: radiation therapy

Genetics Home Reference related topics:   breast cancer   

MedlinePlus related topics:   Breast Cancer    Cancer   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Active Control
Official Title:   Prospective Randomised Clinical Trial Testing 5.7 Gy and 6.0 Gy Fractions of Whole Breast Radiotherapy in Terms of Late Normal Tissue Responses and Tumour Control - FAST

Further study details as provided by National Cancer Institute (NCI):

Estimated Enrollment:   900
Study Start Date:   January 2005

Detailed Description:

OBJECTIVES:

  • Compare late normal tissue effects of standard vs 2 different dose levels of hypofractionated adjuvant whole breast radiotherapy, in terms of changes in photographic breast appearance, in women with localized breast cancer who are at average or low risk of recurrence.
  • Compare tumor control in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 3 treatment arms.

  • Arm I (control): Patients undergo standard radiotherapy 5 days a week for 5 weeks.
  • Arm II: Patients undergo hypofractional radiotherapy once a week for 5 weeks.
  • Arm III: Patients undergo hypofractional radiotherapy (at a lower dose than arm II) once a week for 5 weeks.

After completion of study treatment, patients are followed annually for 5-10 years.

PROJECTED ACCRUAL: A total of 900 patients (300 per treatment arm) will be accrued for this study within 12 months.

  Eligibility
Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of invasive carcinoma of the breast

    • Localized disease

      • Pathological tumor size < 3.0 cm in diameter
      • Axillary node negative
  • At average or low risk of local tumor recurrence
  • Must have undergone prior breast-preserving surgery

    • No prior mastectomy
    • Complete microscopic resection of tumor
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 50 and over

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Other

  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • No prior neoadjuvant or adjuvant cytotoxic chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No concurrent lymphatic radiotherapy
  • No concurrent radiotherapy boost to the breast

Surgery

  • See Disease Characteristics
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00107497

Locations
United Kingdom
Halton Hospital - North Cheshire Hospitals NHS Trust    
      Cheshire, United Kingdom, WA7 2DA
Hereford Hospitals NHS Trust    
      Hereford, United Kingdom, HR1 2ER
United Kingdom, England
Berkshire Cancer Centre at Royal Berkshire Hospital    
      Reading, England, United Kingdom, RG1 5AN
Cheltenham General Hospital    
      Cheltenham, England, United Kingdom, GL53 7AN
Royal Cornwall Hospital    
      Truro, Cornwall, England, United Kingdom, TR1 3LJ
Clatterbridge Centre for Oncology NHS Trust    
      Merseyside, England, United Kingdom, CH63 4JY
Cumberland Infirmary    
      Carlisle, England, United Kingdom, CA2 7HY
Ipswich Hospital NHS Trust    
      Ipswich, England, United Kingdom, IP4 5PD
Christie Hospital NHS Trust    
      Manchester, England, United Kingdom, M20 4BX
Royal Devon and Exeter Hospital    
      Exeter, England, United Kingdom, EX2 5DW
Royal Marsden NHS Foundation Trust - Surrey    
      Sutton, England, United Kingdom, SM2 5PT
Royal Shrewsbury Hospital    
      Shrewsbury, England, United Kingdom, SY3 8XQ
Southend University Hospital NHS Foundation Trust    
      Westcliff-On-Sea, England, United Kingdom, SS0 0RY
Sussex Cancer Centre at Royal Sussex County Hospital    
      Brighton, England, United Kingdom, BN2 5BE
Torbay Hospital    
      Torquay Devon, England, United Kingdom, TQ2 7AA
University Hospital of North Staffordshire    
      Stoke-On-Trent, England, United Kingdom, ST4 7LN
Worcester Royal Hospital    
      Worcester, England, United Kingdom, WR5 1DD
Worthing Hospital    
      Worthing, England, United Kingdom, BN11 2DH
United Kingdom, Wales
Velindre Cancer Center at Velindre Hospital    
      Cardiff, Wales, United Kingdom, CF14 2TL

Sponsors and Collaborators
Institute of Cancer Research, United Kingdom

Investigators
Study Chair:     John R. Yarnold, MD, FRCR     Royal Marsden - Surrey    
  More Information


Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site
 

Study ID Numbers:   CDR0000417730, ICR-04/MRE06/17, ICR-FAST, ICR-FAST-04/MRE06/17, EU-20506
First Received:   April 5, 2005
Last Updated:   March 22, 2008
ClinicalTrials.gov Identifier:   NCT00107497
Health Authority:   United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I breast cancer  
stage II breast cancer  

Study placed in the following topic categories:
Skin Diseases
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on September 23, 2008




Links to all studies - primarily for crawlers